Skip to main content
HROW logo

HROW · Harrow, Inc.

Track HROW — free
$32.00 -0.13 (-0.40%)
Market Cap
$1.21B
Shares
37.53M
Volume · Nov 19 762.87K Avg daily vol (3M) 617.04K

Price & Indicators

 

Key stats

Close
$32.13
Open
$31.99
Day range
$31.39–32.47
52-week closing range
$26.04–54.80
Average volume, 30 days
708K
Short interest
7.1M · 18.9% of shares · 14.1 days
Short volume, last session
59%
Last earnings
Nov 10, 2026
Latest filing
10-Q · Nov 9
Price history
Jan 2020 to Nov 2026

Up next

Feb 10, 2027 Est · unconfirmed · in 12 wks

Latest documents

2026
Nov 18
Investor event
Record third-quarter revenue tops $99 million

Harrow reported record third-quarter revenue of better than $99 million. It guided revenue of between $350 and $365 million this year and fourth-quarter adjusted EBITDA of better than $33 million.

4 source passages
The third quarter of this year was a record quarter for HARO. We did better than $99 million, just a whisker under $100 million in revenue. We've guided that we'll do between $350 and $365 million this year. We've guided that in the fourth quarter, we'll do better than $33 million in adjusted EBITDA, and that's up from the $21.2 million that we recently reported. Open the document at this passage
Nov 16
Current report 8-K
Record Q3 revenue of $99.3M; 2026 guidance $350M–$365M

Harrow furnished a November 2026 investor presentation for the Jefferies Global Healthcare Conference, reporting Q3 2026 revenue of $99.3M and full-year 2026 revenue guidance of $350M–$365M.

Regulation FD disclosure
3 source passages
Investor Presentation Jefferies Global Healthcare Conference London | November 2026 Q3 2026 $99.3M Revenue 41% growth vs. Q2 $83.5M Branded Revenue 2026 Guidance $350M–$365M Full Year 2026 Revenue Open the document at this passage
Nov 10
Earnings call
Revenue guidance held; adjusted EBITDA outlook cut

Harrow reported record third-quarter revenue of $99.3 million, reaffirmed full-year revenue guidance of $350 million to $365 million, and reduced its adjusted EBITDA outlook to more than $40 million.

4 source passages
Good morning, and welcome to Harrow's third quarter 2026 earnings conference call. Third quarter revenue was a record $99.3 million, up 41% sequentially and 39% year-over-year. Turning to our outlook, we are reaffirming full-year revenue guidance of $350 million to $365 million. We're updating our full-year adjusted EBITDA outlook to more than $40 million, including more than $33 million in the fourth quarter, compared with our previous guidance of $80 million to $100 million. Open the document at this passage
Nov 9
Quarterly report 10-Q FY2026 Q3, ended Sep 30
Revenue rose to $99,297,000; TYRVAYA deal closed

Harrow’s total revenues, net rose to $99,297,000 for the three months ended September 30, 2026. It completed the $30,000,000 TYRVAYA acquisition on October 1, 2026 and expects revenue in excess of $30,000,000 in 2027.

Revenue $99.3M ▲ 38.6% Net income $9.76M ▲ 856.6% Diluted EPS $0.25 ▲ 733.3%
Read from the MD&A section
5 source passages
The following presents our revenues for the three and nine months ended September 30, 2026 and 2025: Total revenues, net | 99,297,000 | 71,638,000 | 27,659,000 | 214,161,000 | 183,211,000 | 30,950,000 On October 1, 2026, we completed the acquisition of TYRVAYA® (varenicline solution) nasal spray 0.03 mg from Viatris, acquiring rights to the product in all countries of the world other than Japan. We paid $30,000,000 in cash at closing, funded with cash on hand, and may be obligated to pay up to an additional $70,000,000 in contingent milestone payments if specified TYRVAYA net sales thresholds are achieved over twelve-month measurement periods ending on or before December 31, 2029. Based on our current expectations, we anticipate that TYRVAYA will contribute in excess of $30,000,000 of revenue in 2027, and that we will incur approximately $20,000,000 of new annual operating expenses primarily as a result of the expansion of our commercial organization, marketing activities and incremental quality, supply chain and serialization costs. As of October 31, 2026, Moody’s Investors Service maintained a Long-Term Corporate Family Rating of B3 for Harrow, Inc. with a Stable Outlook and Fitch Ratings maintained a Long-Term Issuer Default Rating of B- with a Stable Outlook for Harrow, Inc. and a rating of B for our senior unsecured notes due September 2030, with a Recovery Rating of RR3. Open the document at this passage
Nov 9
Current report 8-K
Adjusted EBITDA guidance cut despite record quarterly revenue

Harrow reported record third-quarter revenue of $99.3 million and GAAP net income of $9.8 million, but lowered full-year 2026 Adjusted EBITDA guidance to more than $40 million from $80 million to $100 million.

Financial results, Regulation FD disclosure Read from the first part of this long document
4 source passages
Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America, announced results for the third quarter ended September 30, 2026. Record third quarter revenue of $99.3 million, up 41% sequentially and 39% year over year GAAP net income of $9.8 million, including a $5.0 million litigation settlement gain, compared with a net loss of $17.3 million in the second quarter of 2026 and net income of $1.0 million in the third quarter of 2025 Reaffirmed full-year 2026 revenue guidance of $350 million to $365 million; updated full-year 2026 Adjusted EBITDA guidance to more than $40 million, including fourth quarter Adjusted EBITDA of more than $33 million, compared with prior Adjusted EBITDA guidance of $80 million to $100 million Open the document at this passage
All documents

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
$303.25M
Trailing 12 months
Net income (TTM)
−$28.49M
Trailing 12 months
Revenue growth YoY
+38.6%
Year over year
Operating margin
-2.0%
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
-1.7%
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
−$205.36M
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
-0.9%
Year over year · fewer shares
Price change (1Y)
-18.9%
Trailing year
Short interest
18.9%
Latest settlement · 14.1 days to cover
View all 125 metrics

AI Brief

Q3 FY26 earnings call · Nov 10, 2026
Q3 FY26

TL;DR. Record quarterly revenue, strong VEVYE and TRIESENCE performance, reaffirmed revenue guidance, and an accelerated G-MELT NDA submission are the key positives. The key negatives are the substantial adjusted EBITDA guidance reduction, first-half revenue miss, lower-than-expected gross margins, QUELL's missed primary endpoint, BYOOVIZ's launch revenue miss, and negative nine-month operating cash flow.

Bullish
  • + Third-quarter revenue reached a record $99.3 million, up 41% sequentially and 39% year over year.
  • + Branded revenue rose 62% year over year to $83.5 million and represented approximately 84% of total revenue.
  • + VEVYE delivered record revenue and prescription growth and secured a major coverage win.
  • + TRIESENCE delivered record quarterly revenue and unit demand.
  • + Full-year revenue guidance was reaffirmed at $350 million to $365 million.
  • + G-MELT remains on track for an NDA submission before the end of 2026, meaningfully ahead of schedule.
Bearish
  • − Full-year adjusted EBITDA guidance was reduced from $80 million-$100 million to a floor of more than $40 million.
  • − First-half revenue finished approximately $28 million below the midpoint of initial guidance.
  • − Gross margins were lower than expected because of compounding-revenue margins and product mix.
  • − The QUELL study failed to establish IHEEZO's non-inferiority on its primary endpoint.
  • − BYOOVIZ generated a revenue miss relative to launch expectations.

AI-generated from the earnings call and 8-K · may contain errors · not investment advice

Equibles Rating

blended score · not investment advice
Overall
Neutral
SellHoldBuy
Technical Neutral Momentum Weak Sentiment Neutral Fundamentals Excellent Quant / Vol Very High
Market backdrop VIX 28.4 · fear Equity put/call 0.72
Technical
price trend
Neutral
50 / 200-day cross No cross
Price vs 200-day avg −14%
below
Price vs 50-day avg +6%
above
RSI (14) 60
neutral
MACD trend Positive
52-week position 21%
mid-range
Volume (OBV) Confirms
volume backs price
Momentum
relative strength
Weak
1-month return +14%
trailing
6-month return −6%
trailing
YTD return −34%
this year
Relative strength 0%
vs S&P · 6-mo
Sentiment
smart money
Neutral
Trend (MA cross) No cross
50d $30 › 200d $37 — 200d above 50d
Institutional flow Distributing
-7% holders QoQ · +25 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Falling
18.90% of shares out · ▼ -5.1% MoM · 14.1 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
210 holders — mid 3-yr range
Squeeze score 86
high risk · 0–100
Fundamentals
Excellent
Revenue growth +36%
Y/Y
Gross margin 75%
contracting
EPS growth +71%
Y/Y
Free cash flow $43.0M
Balance sheet $177.1M
net debt
Quant / Vol
risk profile
Very High
Volatility 63%
annualized · 1-yr
Max drawdown −52%
past year
ATR 5.6%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Guidance & track record

Beat or met 3 of last 4
Latest guidance · from the Earnings Call filed Nov 10, 2026
full-year
Revenue $350M – $365M
Adjusted EBITDA Non-GAAP at least $40M
Q4
Revenue $136M – $151M
fourth quarter
Adjusted EBITDA Non-GAAP at least $33M
next year
Revenue at least $30M
Revenue at least $30M
Previous outlook earlier release · from the 8-K filed Nov 9, 2026

Still-open targets the latest release did not restate under the same label.

Revenue · full-year 2026 $350M – $365M
Adjusted EBITDA · full-year 2026 at least $40M
Adjusted EBITDA · fourth quarter at least $33M
Fourth-quarter revenue · fourth quarter $136M – $151M
Fourth-quarter Adjusted EBITDA · fourth quarter at least $33M
Adj. EBITDA · FY’26 at least $40M
Adj. EBITDA · Fourth-quarter at least $33M
Prior guidance period ended · from the 8-K filed May 11, 2026
Revenue · Second Quarter $71M – $81M
Guided vs delivered · last 4 settled
Revenue Second Quarter
guided $71M – $81M
$70.66M Miss −7.0%
Full year revenue outlook full year 2025
guided $270M – $280M
$272.3M In line
Revenue 2024
guided at least $180M
$199.61M In line
Revenues 2023
guided $129M – $136M
$130.19M In line

Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

Technicals

trend & momentum for long-term holders Neutral
1 · 4 · 2
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
−14% Bearish
Price vs 50-day avg
+6% Bullish
RSI (14)
60 Neutral
MACD trend
Positive Bullish
52-week position
21% Neutral
Volume (OBV)
Confirms Neutral
Market signals — smart money & positioning
Mixed
Trend (MA cross) No cross
50d $30 › 200d $37 — 200d above 50d
Institutional flow Distributing
-7% holders QoQ · +25 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Falling
18.90% of shares out · ▼ -5.1% MoM · 14.1 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
210 holders — mid 3-yr range
Price context
position in its 52-week range
Range low $26 Now $32 · 21% Range high $55
vs 200-day avg -14% vs 50-day avg +6%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

the company's own KPIs, from written earnings releases and filings
Metric Latest Period YoY
ADJ. EBITDA non-GAAP $21.2M Q3 2026 —
GAAP gross margin 75% the third quarter of 2026 —
Record quarterly unit demand 20,022 Third Quarter 2026 —
Segment contribution (Branded) $20,911,000 the three months ended September 30, 2026 filing —
Segment contribution (Compounding) $712,000 the three months ended September 30, 2026 filing —
Sequential Unit Growth 37% Q3 2026 vs. Q2 2026 —
Unit demand 62,210 Third Quarter 2026 —
Branded TRx market share 14.6% Q2 2026 —
Compounding gross margin 52.8% Three Months Ended June 30, 2026 filing —
Reorder rate 85.5% Q2 2026 —

Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period

Versus peers

Drug Manufacturers - Specialty & Generic — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
HROW
Harrow, Inc.
this stock
$1.21B -34.4% +36.4% — 18.9%
TAK
Takeda Pharmaceutical Co Ltd
$68.40B +37.3% — — 0.1%
GALDY
Galderma Group AG
$50.89B +5.3% — — 0.0%
TEVA
Teva Pharmaceutical Industries Ltd
$44.97B +23.5% +4.3% 87.6 2.4%
JHPCY
Jiangsu Hengrui Pharmaceuticals Co., Ltd.
$40.66B — — — 0.0%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Accumulating
Holders
210
% held
60.2%
Net QoQ
+1.1M sh
Top holder
BlackRock, Inc.
Held Float
View
Held by Funds
Fund positions
163
View
Short & Settlement
Short Interest Falling
Shares short
7.1M
Days to cover
14.1d
Change
-382.4K sh
View
Short Volume
Short vol %
59%
As of
Nov 19, 2026
Short Total
View
Fails to Deliver
FTD shares
300
Value
$8.7K
As of
Oct 28, 2026
View
Off-Exchange
Off-exchange %
44.0%
Week of
Oct 12, 2026
Off-exch Lit
View
Financials
Financials
Revenue (FY)
$272.3M
Net income (FY)
$-5.1M
EPS diluted
$-0.14
View
Filings
SEC Filings
Latest
Investor Event Transcript
Filed
Nov 18, 2026
This year
23

Harrow reported record third-quarter revenue of better than $99 million. It guided revenue of between $350 and $365 million this year and fourth-quarter adjusted EBITDA of better than $33 million.

View
Proposed Sales
Value
$450.0K
Shares
11.3K
Filed
Aug 21, 2026
View
Exempt Offerings
Offering
$10.7M
Filed
May 14, 2021
View
Earnings & Events
Webcasts
Last webcast
Nov 18, 2026
View
Investor Relations
Latest news
Harrow Announces Third Quarter 20…
Published
Nov 9, 2026
View

Performance

5D 20D 120D MTD YTD
HROW +13.5% +14.1% -5.8% +13.8% -34.4%
SPY -5.5% -6.3% -5.6% -5.3% +5.0%
vs SPY +19.0% +20.4% -0.2% +19.0% -39.4%
Key facts CIK 1360214 CUSIP 415858109 13F (30d) 212 filings 189 filers Visit website Investor relations